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This study investigated the effects of free paclitaxel (PTX) and PTX-loaded in pyromellitic 
nanosponges (PTX-PNS) in reducing in vitro and in vivo melanoma cell growth and 
invasivity, and in inhibiting angiogenesis. To test the response of cells to the two PTX 
formulations, the cell viability was evaluated by MTT assay in seven continuous cell lines, 
in primary melanoma cells, both in 2D and 3D cultures, and in human umbilical vein 
endothelial cells (HUVECs) after exposure to different concentrations of PTX or PTX-PNS. 
Cell motility was assessed by a scratch assay or Boyden chamber assay, evaluating 
cell migration in presence or absence of diverse concentrations of PTX or PTX-PNS. 
The effect of PTX and PTX-PNS on angiogenesis was evaluated as endothelial tube 
formation assay, a test able to estimate the formation of three-dimensional vessels in 
vitro. To assess the anticancer effect of PTX and PTX-PNS in in vivo experiments, the two 
drug formulations were tested in a melanoma mouse model obtained by B16-BL6 cell 
implantation in C57/BL6 mice. Results obtained were as follows: 1) MTT analysis revealed 
that cell proliferation was more affected by PTX-PNS than by PTX in all tested cell lines, in 
both 2D and 3D cultures; 2) the analysis of the cell migration showed that PTX-PNS acted 
at very lower concentrations than PTX; 3) tube formation assay showed that PTX-PNS 
were more effective in inhibiting tube formation than free PTX; and 4) in vivo experiments 
demonstrated that tumor weights, volumes, and growth were significantly reduced by 
PTX-PNS treatment with respect to PTX; the angiogenesis and the cell proliferation, 
detected in the tumor samples with CD31 and Ki-67 antibodies, respectively, indicated 
that, in the PTX-PNS-treated tumors, the tube formation was inhibited, and a low amount 
of proliferating cells was present. Taken together, our data demonstrated that our new 
PTX nanoformulation can respond to some important issues related to PTX treatment, 
lowering the anti-tumor effective doses and increasing the effectiveness in inhibiting 
melanoma growth in vivo.
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INTRODUCTION
Melanomas are a heterogeneous group of aggressive and 
highly metastatic tumors (Radovic et al., 2012), representing 
the deadliest form of skin cancer. Nearly half of patients with 
metastatic melanomas harbor a valine–glutamine substitution 
in codon 600 of the serine/threonine kinase BRAF (BRAFV600 
mutation) (Davies et al., 2002). BRAF inhibitors (BRAFi) target 
selectively the BRAF V600E/K genetic alteration and are widely 
used to treat melanoma patients harboring BRAFV600 mutation. 
Treatment with BRAFi results in high response rates. However, 
responses are short-lived, with a median time to progression of 
5.1–8.8 months (Flaherty et al., 2010; Robert et al., 2015). The 
addition of a MEK inhibitor to a BRAFi extends the median 
duration of response from 5.6 to 9.5 months (Long et al., 2017).
Similar results have been observed in patients treated with 
anti–PD-1 (tumor programmed death ligand 1) monotherapy or 
a combination of anti–PD-1 and anti–CTLA-4 agents. A recent 
overall survival (OS) analysis of the phase 3 KEYNOTE-006 
trial showed a 33-month OS rate of 50% in patients receiving 
pembrolizumab monotherapy, an anti-PD-1 monoclonal antibody 
(Robert et al., 2017). Despite the efficacy of BRAF-targeted 
and PD-1-related immune therapies in treating metastatic 
melanoma, a significant number of patients exhibit resistance. 
Although chemotherapeutic drugs, including dacarbazine, 
cisplatin, and paclitaxel (PTX), have been used, alone or in 
combination, without significant survival rate improvement 
(Bhatia et al., 2009), some patients with metastatic melanoma 
present remarkable responses to chemotherapeutic agents, even 
in the absence of a response to modern targeted therapies and 
immunotherapies (Simon et al., 2017).
PTX was originally isolated from the bark of the Pacific 
yew tree, Taxus brevifolia, and phase II clinical trials suggested 
that it had clinical activity in melanoma (Walker et al., 2005). 
In addition to the microtubule-stabilizer function and the 
induction of cytotoxicity, PTX has been found to induce 
immunogenic cell death, which results in augmented CD8+ 
T cell priming and cytotoxic activity (Song et al., 2017), 
regulating the immunosuppressive microenvironment in tumor 
(Pfannenstiel et al., 2010). However, free PTX showed non-
selective distribution and poor water solubility (less than 0.3 
μg/ml) (Konno et al., 2003). The common PTX formulation 
approved consists of Cremophor EL® and ethanol solution, but 
these solvents present severe side effects. To overcome these 
limitations, PTX has been embedded in drug nanotherapeutics, 
including albumin and polymeric micelle nanoparticles 
to treat several types of tumors (Sofias et al., 2017). These 
nanoformulations can reduce serious adverse effects of PTX, 
like allergic reactions, nephrotoxicity, and neurotoxicity, but 
some of them showed insufficient solubilizing capacity and 
poor stability (Mittal et al., 2018). For instance, Abraxane®, 
human serum albumin-bound PTX nanoparticle, approved by 
FDA in 2005, reduced off-targeted side effects and improved 
antitumor efficacy, but after i.v. administration, Abraxane® 
rapidly dissociates into the individual constituents. Moreover, 
the pharmacokinetics and the biodistribution of PTX are not 
improved (Chen et al., 2018). Thus, identification of non-toxic 
formulations capable to deliver PTX to the target site and release 
it in a sustained manner is needed to avoid the nonspecific 
biodistribution and to prevent the toxicity due to excessive dose 
of the drug. The novel pyromellitic nanosponges (PNS) showed 
the capability to act as PTX nanocarrier able to store and release 
it slowly and in a prolonged manner.
In this paper, we compare the effectiveness of free PTX 
and PTX-loaded PNS (PTX-PNS) in inhibiting in vitro and 
in vivo melanoma cell growth and invasiveness and in inhibiting 
angiogenesis.
MATERIALS AND METHODS
Preparation of PTX-Loaded Pyromellitic 
Nanosponges
PNS were synthetized by reacting β-cyclodextrin with pyromellitic 
anhydride as crosslinking agent at 1:4 molar ratio (CD/cross-linker). 
To transform the coarse PNS powder into a nanoformulation 
suitable for intravenous administration, a top down method was 
tuned. PNS were suspended in saline solution (NaCl 0.9% w/v) at 
the concentration of 10 mg/ml and homogenized using a high-shear 
homogenizer Ultra-Turrax (10 min, 24,000 rpm). Then, a high-
pressure homogenization (HPH) step was performed to reduce 
the PNS size, using a high-pressure homogenizer (EmulsiFlex 
C5, Avastin, 90 min, 500 bar). The PNS nanosuspension was then 
purified by dialysis (membrane cutoff 12,000 Da). PTX-PNS were 
obtained by adding PTX solubilized in 50 µl of isopropanol to 
the blank PNS nanosuspension. The mixture was stirred at room 
temperature for 24 h.
Physico-Chemical Characterization of  
PTX-Loaded Pyromellitic Nanosponges
Size, polydispersity index, and zeta potential values of blank and 
PTX-PNS were measured by dynamic light scattering using a 
90 Plus particle sizer (Brookhaven Instruments Corporation, USA). 
The measurements were performed using diluted PNS samples at a 
fixed angle of 90° and at a temperature of 25 °C. For zeta potential 
determination, the samples were placed in the electrophoretic cell, 
where an electric field of about 15 V/cm was applied.
The PNS morphology was evaluated by transmission electron 
microscopy (TEM) analysis, using a Philips CM 10 transmission 
electron microscope. PNS samples were sprayed on Formvar-
coated copper grid and air-dried before observation.
Paclitaxel High Performance Liquid 
Chromatography (HPLC) Quantitative 
Determination
PTX quantitative determination was carried out by HPLC 
analysis using a pump (Perkin Elmer Pump 250B, Waltham, 
MA) equipped with a spectrophotometer detector (Flexar UV/
Vis LC spectrophotometer detector, Perkin Elmer, Waltham, 
MA). A reverse phase Agilent TC C18 column (150 cm × 4.6 mm, 
pore size 5 μm; Agilent Technologies, Santa Clara, CA, USA) 
was used. The column was eluted with acetonitrile/water (60:40) 
at a flow rate of 1 ml/min. PTX was detected at 227 nm with 
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a UV/vis detector. The drug concentration was calculated using 
the external standard method from a standard calibration curve.
In vitro Release Studies
The release kinetics of PTX from PTX-PNS was in vitro 
evaluated. In vitro drug release studies were conducted in a 
multi-compartment rotating cell, comprising a donor chamber 
separated from the receiving phase by a cellulose membrane 
(Spectrapore, cut-off = 12,000 Da); 1 ml of PTX-PNS was 
placed in the donor chamber. The receiving chamber contained 
1 ml of phosphate buffer 0.05 M (pH 7.4 or pH 5.5) added with 
10% ethanol to assure drug solubility. The receiving phase was 
withdrawn at regular intervals and completely replaced with the 
same amount of fresh buffer to maintain sink conditions. The 
concentration of PTX in the withdrawn samples was detected by 
HPLC.
Cell Cultures and Treatments
The following human melanoma cell lines were used: A375 from 
the American Type Culture Collection (ATCC; Manassas VA), 
M14, JR8, RPMI7932, PCF-2, and LM from Dr. Pistoia (Gaslini 
Institute, Genoa, Italy). The mouse melanoma B16-BL6 cell line 
was obtained from RIKEN, Saitama, Japan (RIKEN is Japan’s 
largest comprehensive research institution renowned for high-
quality research in a diverse range of scientific disciplines). These 
cells were cultured in RPMI1640 medium, except A375 that were 
cultured in DMEM. Both media were supplemented with 10% 
fetal bovine serum (FBS), 100 units/ml penicillin, and 100 μg/ml 
streptomycin in a 5% CO2, 37 °C incubator. Human umbilical 
vein endothelial cells (HUVECs) were isolated from human 
umbilical veins by trypsin treatment (1%) and cultured in M199 
medium with the addition of 20% FCS, 100 U/ml penicillin, 
100 μg/ml streptomycin, 5 UI/ml heparin, 12 μg/ml bovine 
brain extract, and 200 mM glutamine. HUVEC were grown to 
confluence in flasks and used at the 2nd–5th passages. Use of 
HUVEC was approved by the Ethics Committee of the “Presidio 
Ospedaliero Martini” of Turin and conducted in accordance 
with the Declaration of Helsinki. Written informed consent was 
obtained from patients.
PTX was purchased from Bristol-Myers Squibb (Chester, UK).
Isolation and Characterization of Primary 
Melanoma Cells
The primary melanoma cell line (PMel) was isolated from a 
77-year-old Caucasian male patient with a superficial spreading 
melanoma in vertical growth phase, showing infiltration of the 
papillary dermis and cutaneous ulceration without metastasis. The 
study was approved by the Committee for human Biospecimen 
Utilization (ChBU—Department of Medical Sciences, University 
of Turin). Written informed consent was obtained from the 
patient for tissue to be used in research.
The tissue sample, used for the primary cell culture 
establishment, was collected from the “left-over tissue” (residual 
tissue not used for diagnostic and therapeutic purposes) at the 
Department of Medical Sciences, Pathology Unit, University of 
Torino (Italy), in sterile tubes containing 10 ml of RPMI serum 
free medium, supplemented with 1% penicillin-streptomycin-
fungizone. Primary cell culture isolation was performed as 
described by Annaratone et al. (2013) with minor modifications. 
Briefly, the tissue sample was washed three times with the same 
medium, then finely minced by surgical blades into approximately 
1×1 mm fragments which were incubated at 37 °C with collagenase 
type IV (1 mg/ml; 1∶1 RPMI, final volume 10 ml), for 3–5 h until 
complete disaggregation of fragments was obtained. Digested 
tissue samples were shaken vigorously by hand to disaggregate 
possible residual large clumps. Collagenase activity was blocked 
by addition of 10 ml of RPMI with 10% FBS. After centrifugation 
at 800 rcf for 6 min, the cell pellets were re-suspended in 
complete culture medium. The final cell suspension was seeded 
in petri dishes as passage 0 and kept in a humidified incubator 
with 5% CO2 at 37 °C in DMEM-F12 medium supplemented 
with 10% FBS, 10 ng/ml human epidermal growth factor (EGF), 
5 mg/ml insulin, 400 ng/ml hydrocortisone, 1% L-glutamine, and 
1% penicillin-streptomycin-fungizone (Sigma-Aldrich). Culture 
medium was changed first at the time of cell attachment and, 
subsequently, three times a week. After three passages, the cells 
were characterized for two specific melanoma markers, S100 and 
HMB45 by immunocytochemistry (ICC). ICC was performed 
by using an automated slide processing platform (Ventana 
BenchMark XT Autostainer, Ventana Medical Systems, Tucson, 
AZ, USA). The anti-S00 and the anti-HMB45 antibodies were 
purchased from DAKO and used following the manufacturer’s 
instructions (Milan, Italy). Both markers were positive (data not 
show), confirming the isolation of melanoma-type cells. PMel 
cells were maintained in standard 2D cell cultures, in DMEM-F12 
medium supplemented as described above.
Spheroid Formation of Primary Melanoma 
(PMeI) Cells
PMel cells, cultured in standard 2D condition, were dissociated 
with trypsin-EDTA into single-cell suspensions. The cells were then 
seeded on ultra-low attachment (ULA) 96-well flat-bottom plates 
(Sigma). Optimal seeding densities were established such that 
melanoma spheroids for both primary cell lines testes fell within 
a size range of 200 to 500 µm in diameter on day 8, considering 
appropriate for initiating experimental studies. Representative 
images of PMel tumor spheroids obtained on day 8, starting from 
1×104 cells/well, are showed in the Supplementary data, Fig. S1
MTT Assay
The toxic effect of PTX or PTX-PNS was determined through the 
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
(MTT) assay as previously described (Ciamporcero et al., 2018). 
This colorimetric assay may be interpreted as a measure of both 
cell viability and cell proliferation (Sylvester, 2011). Cells were 
seeded (0.8 – 1.5 × 103 cells/well) in 100 μl of serum-supplemented 
medium and treated with different concentrations of PTX and 
PTX-PNS. Untreated cells or cells treated with the empty PNS 
were used as control. After 72 h, the drug was removed and 
MTT assay was performed. The optical density (OD) of treated 
and untreated cells was determined at a wavelength of 570 nm 
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with a microplate reader after 4 h of incubation. Controls were 
normalized to 100%, and the readings from treated cells were 
expressed as % of viability inhibition. Eight replicates were used 
to determine each data point, and five different experiments were 
performed.
WST-1 Assay
The cytotoxic effect of PTX or PTX-PNS on PMel spheroids was 
determined by using the 2-(4-iodophenyl)-3-(4-nitrophenyl)-
5-(2,4-disulfophenyl)-2H-tetrazolium (WST-1) reagent (Roche, 
Italy). Cells were seeded (0.8 – 1.5 ×103 cells/well) in 100 μl of serum-
supplemented medium and treated with different concentrations 
of PTX, PTX-PNS, or PNS. After 72 h, the drug was removed and 
the WST-1 assay was performed. The OD of treated and untreated 
cells was determined at a wavelength of 450 nm with a microplate 
reader after 4 h of incubation. Controls were normalized to 100%, 
and the readings from treated cells were expressed as % of viability 
inhibition. Eight replicates were used to determine each data 
point, and five different experiments were performed.
Crystal Violet Assay
For the quantitative determination of cells adhering to the plate 
after the 6 h treatment with different concentrations of PTX, 
PTX-PNS, or PNS, the violet crystal test was used. The violet 
crystal is a water-soluble dye with affinity for neutral pH DNA, 
soluble at acidic pH. The cells were washed after treatment, 
fixed, and stained with crystal violet-methanol. After careful 
washing, acetic acid was added and the reading was made with a 
spectrophotometer at 595 nm. The controls were normalized to 
100%, and the readings from treated cells were expressed as % of 
viability inhibition. Four replicates were used to determine each 
data point, and five different experiments were performed.
Cell Motility Assays
In the wound-healing assay, after starvation for 24  h in serum-
free medium, HUVECs were plated onto six-well plates (106 cell/
well) and grown to confluence. Cell monolayers were wounded 
by scratching with a pipette tip along the diameter of the well, and 
they were washed twice with serum-free medium before their 
incubation with diverse concentrations of PTX, PTX-PNS, or 
PNS. Drug concentrations that were not cytotoxic were used for 
this assay. In order to monitor cell movement into the wounded 
area, five fields of each wound were photographed immediately 
after the scratch (T0) and after 24 h (Dianzani et al., 2014). The 
endpoint of the assay was measured by calculating the reduction 
in the width of the wound after 24 h and compared to T0, which 
is set at 100%. The area of wound healing was calculated by using 
the ImageJ software (Schneider et al., 2012).
In the Boyden chamber (BD Biosciences, San Jose, CA) 
invasion assay, cells (2 × 103) were plated onto the apical side 
of 50 μg/ml Matrigel-coated filters (8.2-mm diameter and 
0.5-μm pore size; Neuro Probe, Inc.; BIOMAP snc, Milan, 
Italy) in serum-free medium with or without increasing 
concentration of PTX, PTX-PNS, or PNS. Nontoxic drug 
concentrations were used for this assay. Medium containing 
VEGF-α (10 ng/ml) was placed in the basolateral chamber as 
a chemo attractant for HUVEC and FCS 20% for melanoma 
cancer cells (A2058 and B16-BL6). After 6 h, cells on the 
apical side were wiped off with Q-tips. Cells on the bottom 
of the filter were stained with crystal violet, and all the fields 
were counted with an inverted microscope.
Tube Forming Assay
Nontoxic drug concentrations were used for the tube formation 
assay. HUVECs were seeded onto 48-well plates (5×104/well) 
previously coated with 75 μl of growth factor-reduced Matrigel, 
with or without increasing concentration of PTX, PTX-PNS, or 
PNS. The morphology of the capillary-like structures formed 
by the HUVECs was analyzed by an inverted microscope after 
6 h of culture, and photographed with a digital camera. Tubule 
formation was analyzed with an imaging system (Image-Pro 
Plus Software for microimaging, Media Cybernetics, version 5.0, 
Bethesda, MD, USA). Tube formation was evaluated by counting 
the total number of tubes in three wells, and five different 
experiments were performed. The results were expressed as % 
inhibition of untreated control cell.
In vivo Experiments
Eight-week-old female C57BL6/J mice (Charles River Laboratories, 
Wilmington, MA, USA) were injected subcutaneously (s.c.) 
with B16-BL6 cells (105 cells/mouse). The mice were bred under 
pathogen-free conditions in the animal facility of the Department of 
Health Sciences (UPO, Novara, Italy). All experimental procedures 
were done according to Europeans Guidelines and our Institution’s 
ethics commission. After 7 days from the injections, when average 
tumor dimension reached 5 mm3, mice were randomized in a blind 
fashion into homogenous groups (5 mice per group) and assigned to 
different treatments. Free PTX or PTX-PNS dissolved in NaCl 0.9% 
were administrated by tail injection (100 μl/mouse) at the dose of 
2.5 mg/kg, every 4 days, for four times. Control mice were injected 
with empty PNS dissolved in PBS. Treatment-related toxicity was 
determined by monitoring mouse weight weekly. The tumor size 
was measured with a caliper, and mice were sacrificed 4 days after 
the last injection. Euthanasia, collection of tumor samples, tumor 
weight, and volume determination were performed after 2 weeks 
from the beginning of treatments.
Histology and Immunofluorescence 
Anti-CD31 and Anti-Ki-67 on Tumor 
Sections
Immediately after dissection, tumor samples were embedded 
in OCT compound (Killik, Bio Optica Milano SpA) and stored 
at −80 °C until use. Tumor tissues were cut with a cryostat 
(thickness 4–5 µm) and treated with 4% paraformaldehyde 
(Sigma-Aldrich) diluted in PBS for 5 min at room temperature 
to fix the sample on the glass slides. The samples were then 
blocked with 5% normal goat serum (R&D System) in PBS for 
1  h in  order to  block nonspecific sites to which the primary 
antibody could bind. To detect CD31 and Ki-67 expression, the 
primary antibodies used were a polyclonal rabbit anti-CD31 
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(Abcam, Cambridge, UK) or a monoclonal mouse anti-human 
Ki-67 antigen (DAKO); both diluted 1:50 and were incubated 
over night at 4°C in a humid chamber. The secondary antibody 
used was an anti-rabbit Ig Alexa Fluor 488-conjugated (Thermo-
Fisher), or an anti-mouse Ig Alexa Fluor 546-conjugated 
(Thermo-Fisher); both diluted 1:400, respectively. Then, 
the sections were stained with 0.5 mg/ml of the fluorescent 
dye 4,6-diamidino-2-phenylindole-dihydrochloride (DAPI, 
Sigma-Aldrich) for 5 min to highlight cell nuclei and then 
mounted using prolong anti-fade mounting medium (SlowFade 
AntiFADE Kit, Molecular Probes Invitrogen). The sections were 
then observed by a fluorescence microscope (Leica, Italy) and 
analyzed by Image Pro Plus Software for micro-imaging 5.0 
(Media Cybernetics, version 5.0, Bethesda, MD, USA). Tumor 
microvessel density (MVD) was measured by evaluating the 
CD31-positive area; the numbers of positive cells for Ki-67 was 
calculated in the total tumor area per field upon slide scanning 
(Panoramic midi II, 3D HISTECH, Budapest, Hungary). 
Hematoxylin and eosin (Sigma Aldrich, Milan, Italy) staining 
was performed to assess morphological changes.
Statistical Analysis
Data were expressed as means ± SD. Significance between 
experimental groups was determined by one-way ANOVA 
followed by the Bonferroni multiple comparison post-test using 
GraphPad InStat software (San Diego, CA, USA). Values of p ≤ 
0.05 were considered significant.
RESULTS
Physico-Chemical Characterization  
of PTX-PNS
The physico-chemical parameters of PNS before and after loading 
with PTX are reported in Table 1. The PNS nanoformulations 
showed average diameters of about 300 nm and a negative surface 
charge. The drug incorporation slightly affected the physico-
chemical characteristics. The zeta potential value remained 
enough high to avoid aggregation phenomena.
TEM analysis showed the spherical morphology of PNS 
and confirmed their nanoscale sizes, due to the high pressure 
homogenization step. Figure 1 (panel A) reports the TEM image 
of PTX-loaded PNS.
PNS were able to load PTX in a good extent, showing an 
encapsulation efficiency of about 96.5% and a loading capacity 
of about 8%.
The release profile of PTX from PTX-PNS was investigated 
in vitro at two pH values (Figure 1, panel B). Prolonged in vitro 
release kinetics was demonstrated, and no initial burst effect 
was observed. The sustained release of PTX from the PTX-PNS 
confirmed the drug incorporation in the PNS polymer matrix. 
The percentage of PTX released from the PNS was about 4% at 
pH 7.4 and 10% at pH 5.5 after 24 h, indicating an enhanced 
release kinetics at acidic pH.
Effect of PTX and PTX-PNS on Cell 
Proliferation
To compare the response of cells to free PTX and PTX-PNS, 
we first analyzed cell viability after 72 h of exposure to different 
concentrations of PTX (from 10-7 to 10-9 M) and PTX-PNS or 
TABLE 1 | Physico-chemical characteristics of blank and PTX-loaded PNS 
formulations.
Formulation Average 
diameter
± SD (nm)
Polydispersity
index
Zeta 
potential
± SD (mV)
Blank PNS 307.2 ± 10.6 0.22 ± 0.01 −33.6 ± 4.5
PTX-PNS 316.8 ± 12.1 0.20 ± 0.02 −28.4 ± 3.7
FIGURE 1 | Characterization of PNS formulations. (A) TEM image of PTX-loaded PNS; (B) In vitro release kinetics of PTX from PTX- loaded PNS as a function of pH 
(pH 7.4 or pH 5.5).
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PNS (from 10-10 to 10-13 M). MTT analysis revealed that cells 
were more affected by PTX-PNS than by free PTX. The effective 
concentrations ranged from 10-7 to 10-8 M for the free PTX in 
all cell lines; from 3×10-9 to 10-13 M PTX-PNS in A2058, JR8, 
PCF2; from 3×10-9 to 3×10-12 M PTX-PNS in M14; and from 
3×10-9 to 10-12 M PTX-PNS in A375, RPMI7932, and B16-BL6 
(Figure 2). The empty PNS did not show any toxicity even 
at highest doses, and the MTT values were similar to those 
obtained in untreated cells.
Effect PTX and PTX-PNS in Inhibiting 
Growth of 2D and 3D Cultures of Primary 
Melanoma Cells
In primary melanoma PMel cells, PTX and PTX-PNS showed 
an inhibitory activity of growth at different doses. PTX was 
effective at doses ranging from 10-5 to 10-9 M, whereas PTX-PNS 
was effective at doses ranging from 10-9 to 10-13 M. The empty 
PNS did not show any toxicity (Figure 3A). In 3D spheroids, 
PTX inhibited the growth at concentrations ranging from 10-5 
to 10-9M, whereas PTX-PNS inhibited growth at concentrations 
ranging from 10-9 to 10-13 M (Figure 3B).
Effect of PTX and PTX-PNS in Inhibiting 
Cell Migration
Tumor growth is favored by tumor angiogenesis, which is 
continuously activated in cancer resulting in the accumulation of 
immature and chaotic blood vessels. The acquisition of endothelial 
cell motility represents the first step of angiogenesis. In order to find 
the PTX and PTX-PNS nontoxic concentrations in HUVECs, which 
can be used in the migration test, MTT analysis was performed 
after 24 h. HUVECs were cultured in the presence and absence of 
titrated amounts of the different formulations. Results demonstrated 
that PTX concentration ranging from 10-8 to 10-10 M and PTX-
PNS concentrations ranging from 10-12 to 10-14 M were nontoxic 
for HUVEC cells at 24 h (Supplementary Data, Figure S2). Thus, 
PTX concentrations in the range of 10-8–10-10 M and PTX-PNS 
concentrations from 10-12 to 10-14 M were chosen for the wound-
healing migration test. Analysis of cells ability to migrate into the 
scratch showed that only PTX-PNS inhibited HUVEC migration at 
10-12 M (Figure 4A and B), while PTX was unaffective.
To confirm these results, cell motility was measured by using 
a Boyden chamber assay, assessing the capability of directional 
migration and invasion. In order to find the PTX and PTX-PNS 
concentrations that were not cytotoxic in HUVECs and melanoma 
FIGURE 2 | Inhibition of melanoma cell proliferation following PTX and PTX-PNS treatment. Cells were treated with increasing concentrations of PTX (from 10-7 to 
10-9 M) or PTX-PNS (from 10-10 to 10-13 M) for 72 h. The results are expressed as % inhibition of control and are the mean ± SD of five separated experiments.  
**p < 0.01 vs control and PNS, *p < 0.05 vs control and PNS, §§p < 0.01 vs PTX, §p < 0.05 vs PTX.
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FIGURE 3 | Inhibition of primary melanoma cell growth following PTX and PTX-PNS treatment. Primary melanoma cells (A) in 2D or (B) in 3D cultures were treated 
with increasing concentrations of PTX (from 10-5 to 10-9 M) or PTX-PNS (from 10-9 to 10-13 M) or PNS (10-9 M) for 72 h. The results are expressed as % inhibition of 
control and are the mean ± SD of five separated experiments. **p < 0.01 vs control and PNS, §§p < 0.01 vs PTX.
FIGURE 4 | Wound-healing assay of HUVEC treated with different concentrations of PTX and PTX-PNS. A scratch was made through the HUVEC layer, and then, 
cells were cultured in the absence (C) or in presence of PTX (from 10-8 to 10-10 M) or PTX-PNS (from 10-12 to 10-14 M) or PNS (10-12 M) for 24 h.  
(A) Microphotographs of the wounded area were taken immediately after the scratch (0 h) and after 24 h, in order to monitor cell migration into the wounded area. 
(B) The graph shows mean ± SD (n = 5) of assay endpoints measured by calculating the reduction in the width of the wound after 24 h and compared to T0 which 
is set at 100%. The area of wound healing was calculated by using the ImageJ software. ∗∗p < 0.01 vs C, §p < 0.05 vs PTX.
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cells, crystal violet assay was performed after 6-h treatments with 
titrated amounts of the diverse formulations. Results demonstrated 
that cell viability was not affected by any concentration of the drug 
formulations tested (Supplementary data, Table S1). The invasion 
experiments demonstrated that PTX and PTX-PNS inhibited 
HUVEC invasion in a concentration dependent-manner; PTX was 
active at 10-8–10-9 M, whereas PTX-PNS affected cell invasion at 
concentrations ranging from 10-12 to 10-13 M (Figure 5A). Similar 
results were obtained for human and mouse melanoma cell lines 
(Figure 5B and C). Representative images of crystal violet staining 
Matrigel-coated filters of the Boyden chambers were reported in 
Supplementary Data, Figure S3.
PTX and PTX-PNS inhibit angiogenesis
The effect of PTX and PTX-PNS on angiogenesis was evaluated 
in endothelial tube formation assay, which is able to estimate the 
formation of three-dimensional vessels in vitro. HUVECs were 
seeded onto 24-well plates (5×104 cell/well) previously coated 
with 75 μl of growth factor-reduced Matrigel (BD Biosciences), 
in the absence or presence of nontoxic concentrations of PTX 
(10-7–10-10M) or PTX-PNS (10-10–10-14M) (Supplementary 
Data, Table S1). The morphology of capillary-like structures 
formed by HUVEC was analyzed 6 h after culturing. The results 
showed that PTX and PTX-PNS dose-dependently inhibited 
endothelial tube formation (Figure 6A). Quantification of the 
FIGURE 5 | Effect of PTX and PTX-PNS on motility of HUVEC (A), A2058 (B), and B16-BL6 (C) assessed by Boyden chamber assay. HUVECs were plated onto 
the apical side of Matrigel-coated filters in the presence and absence of either PTX (from 10-8 to 10-10 M) or PTX-PNS (from 10-12 to 10-14 M). Medium containing 
VEGF-α (10 ng/ml) or FCS 20% was placed in the basolateral chamber as a chemoattractant for HUVECs or melanoma cell line, respectively. After 6 h, cells on 
the apical side were wiped off with Q-tips. Cells on the bottom of the filter were stained with crystal violet, and all counted with an inverted microscope. Data are 
expressed as mean ± SD (n = 5) of number of migrated cells. ∗∗p < 0.01, vs VEGF-α or FCS, §§p < 0.01, vs PTX.
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inhibition is shown in Figure 6B. PTX inhibited tube formation 
at the doses ranging from 10-7 to 10-9 M, whereas PTX-PNS were 
more effective inhibiting tube formation at the doses ranging 
from 10-10 to 10-13 M.
PTX and PTX-PNS Anticancer Effect 
in Xenograft Tumor Model
To assess the anticancer effect of PTX and PTX-PNS in in vivo 
experiments, we implanted B16-BL6 cells, in C57/BL6 mice, and 
we treated animals with the two drug formulations. Results showed 
that tumor weights (Figure 7A), volumes (Figure 7B), and growth 
(Figure 7C) were significantly reduced by PTX-PNS treatment 
compared to those detected in the mice treated with either PBS, 
empty PNS, or free PTX at the dose of 2.5 mg/kg. By contrast, PTX 
did not show any significant effect. Analysis of tumor vasculature 
was assessed by staining CD31 in the tumor sections and showed 
that vascular density (MVD) was significantly lower in the tumors 
from mice treated with PTX-PNS than in those treated with either 
PBS, empty PNS, or free PTX (Figure 8A and B). The number of 
positive cells for Ki-67 (Figure 8C and D) confirmed previous 
results. All treatments were well tolerated by the animals without 
significant weight loss in any group.
DISCUSSION
The use of nanodelivery systems offers some advantages that can 
improve the therapeutic efficacy of anticancer drugs. Indeed, 
nanoformulations could increase drug concentration at the tumor 
site, decreasing the total dose administered, and subsequently 
reducing the side effects (Duchene et  al., 2016, Prasad et al., 
2018). In particular, cyclodextrin-based nanosponges (NS) 
have been proposed for cancer nanotherapeutic development 
(Trotta et al., 2012, Trotta et al., 2014; Swaminathan et al., 2016). 
The use of NS as nanocarrier for PTX delivery was previously 
investigated. PTX was encapsulated in NS obtained by reacting 
CDs with diphenylcarbonate as cross-linker (Ansari et al., 2011).
The in vivo behavior of PTX-NS was studied after oral 
administration to rats, showing an increase of the drug oral 
bioavailability (Torne et al., 2010). Moreover, PTX showed the 
capability to be incorporated in a great extent in another type of NS, 
obtained using carbonyldiimidazole as crosslinking agent (Mognetti 
et al., 2012). Here, we evaluated the use of PNS as nanovehicle of 
PTX. Previously, PNS showed non-toxic effect in vitro and in vivo 
in acute and repeated dose toxicity studies (Shende et al., 2015). 
PNS were able to incorporate PTX, increasing its apparent aqueous 
solubility. Indeed, it has an extremely low aqueous solubility (less 
FIGURE 6 | Tube formation assay of HUVEC treated with different concentrations of PTX or PTX-PNS. HUVEC were plated in the presence and absence of PTX 
(from 10-7 to 10-10 M) or PTX-PNS (from 10-10 to 10-14 M). (A) The morphology of the capillary-like structures formed by the HUVEC was analyzed by an inverted 
microscope after 6 h of culture, and photographed with a digital camera. (B) The graph shows the tube formation, evaluated by counting the total number of tubes 
in three wells of five different experiments. The results were expressed as % inhibition of untreated control cells. Data are expressed as mean ± SD. ∗∗p < 0.01, 
vs.VEGF-α or FCS, ∗p < 0.05, vs VEGF-α or FCS, §§p < 0.01, vs. PTX, §p < 0.05, vs PTX.
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than 0.3 µg/) and it is currently dissolved in a mixture of Cremophor 
EL® (polyoxyethyleneglycerol triricinoleate 35) and dehydrated 
ethanol (1:1 v/v) in the commercial intravenous dosage form. 
The PTX incorporation in the PNS nanostructure was confirmed 
by the slow and prolonged in vitro release kinetics of the drug 
from PTX-NS. Interestingly, results demonstrated that PTX-PNS 
inhibited melanoma cell growth more effectively than free PTX. 
The inhibitory activity on cell proliferation was effective on all of the 
melanoma cell lines used in this study, including a PMel. Moreover, 
the cytotoxicity of PTX-PNS was displayed at concentrations 
which were a thousand times lower than those displayed by 
free PTX. PTX-PNS significantly inhibited the proliferation of 
primary tumor cells in both 2D and 3D melanoma cell cultures 
with the same effectiveness. Results on melanoma spheroid 3D 
cultures were particularly relevant since 3D-cultured cells acquired 
morphological and cellular features which are more similar to 
solid tumors than 2D cultures. In particular, Ma et al. (2012) 
compared nanoparticle penetration properties of different culture 
systems and reported that 3D spheroids of HeLa cells displayed 
similar morphologic features of human solid tumors, including a 
resistance to chemotherapeutics that could not be observed in 2D 
cultures. In line with this observation, it has been suggested that 
3D spheroids may be a useful simplified model of tumor tissue for 
in vitro testing of anticancer therapeutics (Edmondson et al., 2014; 
Huang et al., 2015).
The effectiveness of PTX-PNS in 3D cultures demonstrated 
that this nanoformulation is effective on a tumor-like 
environment mimicking several features of tumors involved in 
chemotherapy resistance such as three-dimensional architecture, 
cell–cell interaction, and hypoxia.
Cancer metastasis is associated with stimulation of cancer cell 
migration and invasion of the neighboring tissues. In line with previous 
results, PTX-PNS inhibited cell melanoma invasion at concentrations 
which were much lower than those displayed by free PTX.
Cancer progression is also associated with stimulation of 
tumor neoangiogenesis producing newly formed vessels to feed 
the tumor. This process involves endothelial cell migration and 
generation of tubule-like structures to form vessels. PTX can reduce 
endothelial cell migration at concentrations ranging from 10-7 to 
10-9 M, according to previous reports showing taxane effects on cell 
FIGURE 7 | In vivo experiments on mouse melanoma model. C57BL6/J mice were injected subcutaneously with B16-BL6 cells (105 cells/mouse). 7 days after the 
tumor injection, mice were treated every 4 days for 2 weeks by i.v. injection of PTX, PTX-PNS, and PNS (2.5 mg/kg, 100 μl/mouse) or the same volume of NaCl 
0.9% as control (five mice/group). Mice were sacrificed at the end of the experiment. Graphs show (A) tumor weight (mg, mean ± SD), (B) tumor volume curves 
(cm3, mean ± SD), and (C) tumor growth (cm3, mean ± SD). Tumors were evaluated every 4 days, after the first treatment performed at T1 (i.e., when they were 
palpable). Data are expressed as mean ± SD. ∗p < 0.05, vs VEGF-α or FCS, §§p < 0.01, vs. PTX, §p < 0.05, vs PTX.
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migration (Ballestrem et al., 2000). However, also in this case, PTX-
PNS was much more effective in inhibiting HUVEC migration and 
invasion than free PTX. A similar pattern in in vitro tubulogenesis 
of endothelial cells was observed, since the inhibitory effect of PTX 
was obtained at nanomolar concentrations, in line with previous 
data from Taraboletti et al. (2002). Intriguingly, PTX-PNS were able 
to inhibit tubulogenesis at lower concentrations, than free PTX.
Finally, we demonstrated that PTX-PNS was more effective 
than PTX in inhibiting the in vivo growth of melanoma cells in a 
mouse model also. Indeed, both the weight, the volume, and the 
growth of melanoma were significantly reduced in mice treated 
with PTX-PNS whereas no significant inhibition was obtained 
with the same dose of free PTX. The results on angiogenesis and 
proliferation rate of tumor cells in vivo are in agreement with 
the in vitro experiments since the microvessel density in the 
tumor and the percentage of Ki-67 positive cells was significantly 
decreased by treatment with PTX-PNS, whereas no significant 
effect was obtained upon treatment with free PTX.
Taken together, our data demonstrated that our new PTX 
nanoformulation can respond to some important issues related to 
PTX treatment, such as solubility and toxicity. The PTX incorporation 
in nanosponges might allow to lower the anti-tumor doses and 
increase its effectiveness in inhibiting melanoma cell model.
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FIGURE 8 | (A) Microphotographs of CD31 staining from a representative experiment (green; magnification 200x). (B) Tumor microvessel density (MVD) determined as 
the percentage of CD31-positive area on the tumor sections. Three randomly selected areas from three tumors from each group were analyzed.  (C) Microphotographs 
of Ki-67 staining from a representative experiment (red; magnification 200x). (D) % of Ki-67-positive cells among tumor cells. Three randomly selected areas from three 
tumors from each group were analyzed. *p < 0.05 vs C and PNS, §p < 0.05 vs PTX.
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FIGURE S1 | Spheroids obtained from primary melanoma cell line PMel.
FIGURE S2 | Effect of PTX and PTX-PNS treatments on HUVEC cell viability 
assessed by MTT assay at 24h.
FIGURE S3 | HUVECs, A2058 and B16-BL6 cells photographed after the 
invasion test.
TABLE S1 | Effect of PTX and PTX-PNS treatments on HUVEC, A2058, and 
B16-BL6 on cell viability assessed by crystal violet staining at 6h.
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